rEECur
24 Nov 2020
Trial Summary
The purpose of this study is to determine which of the most commonly used chemotherapy used in recurrent and primary refractory Ewing sarcoma is most beneficial.
Acronym:
rEECur
ACTRN/NCT /ethics:
ACTRN12618001825246
Scientific title:
rEECur: Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Sponsor / Cooperative group:
ANZCHOG
Trial & Patient Characteristics
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | All phases |
| Age Range | 4-50 years old |
| Sex | Both |
| Tumour Stream | Ewing sarcoma |
| Cancer Stage | Metastatic or Widespread; Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2014-11-25 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Nimit Singhal |
| Recruitment Status | Recruiting |